BioNTech SE(BNTX)
![icon](https://files.reportify.cn/fe-static/_next/static/media/search.b3fd6117.png?imageMogr2/quality/75/thumbnail/64x/format/webp)
搜索文档
BioNTech SE (BNTX) CEO Ugur Sahin on JPMorgan 40th Annual Healthcare Conference (Transcript)
2022-01-12 04:34
BioNTech SE (NASDAQ:BNTX) JPMorgan 40th Annual Healthcare Conference Call January 11, 2022 9:45 AM ET Company Participants Ugur Sahin - Co-Founder & Chief Executive Officer Jens Holstein - Chief Financial Officer Sean Marett - Chief Business & Commercial Officer Ozlem Tureci - Chief Medical Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Cory Kasimov - JPMorgan Chase & Co. Cory Kasimov Great. Good morning or good afternoon from the 40th Annual JPMorgan Healthcare Conference. My ...
BioNTech SE(BNTX) - 2020 Q4 - Annual Report
2021-03-30 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...
BioNTech SE(BNTX) - 2019 Q4 - Annual Report
2020-04-01 04:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...